POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium is the major intracellular cation; it maintains intracellular tonicity, transmembrane potential, and normal neuromuscular excitability. Chloride is the major extracellular anion; together with sodium, it maintains extracellular tonicity and acid-base balance.
| Metabolism | Potassium is not metabolized; it is eliminated primarily by the kidneys, with small amounts excreted in feces and sweat. Chloride is also mainly excreted by the kidneys. |
| Excretion | Renal: >90% excreted unchanged in urine; minor fecal elimination (<2%) via biliary route. |
| Half-life | Terminal elimination half-life: 10–20 minutes in healthy individuals; context: reflects rapid renal clearance; prolonged in renal impairment or reduced glomerular filtration rate. |
| Protein binding | Approximately 10% bound to albumin; minimal binding to other plasma proteins. |
| Volume of Distribution | 0.1–0.2 L/kg; clinical meaning: reflects primary distribution in extracellular fluid; larger Vd in hypokalemia due to cellular uptake. |
| Bioavailability | Intravenous: 100%; oral (not applicable here): not relevant for this formulation. |
| Onset of Action | Intravenous: Immediate (within seconds to minutes) due to direct vascular access. |
| Duration of Action | Intravenous: Duration of effect is dependent on continuous infusion; bolus effects may last minutes; context: rapid redistribution and excretion necessitate continuous administration for sustained replacement. |
| Molecular Weight | 74.55 |
40 mEq potassium chloride in 0.9% sodium chloride intravenously at a maximum rate of 10 mEq/hour.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 10-50 mL/min: reduce dose by 25-50%. GFR <10 mL/min: reduce dose by 50% or use with caution. |
| Liver impairment | No specific adjustment for Child-Pugh class. Use with caution in severe hepatic impairment due to risk of electrolyte disturbances. |
| Pediatric use | 0.5-1 mEq/kg/dose intravenously, maximum 40 mEq/dose. Infuse at ≤0.5 mEq/kg/hour. |
| Geriatric use | Start at lower end of dosing range (e.g., 20 mEq) and titrate slowly due to decreased renal function. Maximum infusion rate 10 mEq/hour. |
| 1st trimester | Potassium chloride is generally considered safe in pregnancy when used as a supplement to correct hypokalemia. However, use only if clearly needed and with careful monitoring of serum potassium levels. Excessive potassium can cause hyperkalemia, which may affect maternal and fetal cardiac function. |
| 2nd trimester | Similar to first trimester; potassium supplementation is indicated for hypokalemia. Monitor serum potassium closely to avoid hyperkalemia, which can lead to cardiac arrhythmias and potential fetal distress. |
| 3rd trimester | Potassium chloride is used cautiously in the third trimester, especially near delivery. Hyperkalemia can cause uterine atony and postpartum hemorrhage. Avoid in patients with preeclampsia or impaired renal function. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium crosses the placenta via active transport and passive diffusion, maintaining fetal serum potassium levels slightly higher than maternal. The degree of transfer is regulated to maintain fetal homeostasis. Excessive maternal potassium can lead to fetal hyperkalemia and cardiac effects. |
| Breastfeeding | Potassium is a normal constituent of breast milk, and supplementation to correct maternal hypokalemia is considered compatible with breastfeeding. However, monitor maternal serum potassium to avoid hyperkalemia, which could potentially affect the infant if levels become significantly elevated. No adverse effects have been reported in nursing infants with maternal potassium supplementation. |
| Lactation Rating | L1 |
| Teratogenic Risk | Potassium chloride is an essential electrolyte; no teratogenic effects have been reported at normal physiological levels. In first trimester: no known risk. Second trimester: no known risk. Third trimester: no known risk. High doses may cause maternal hyperkalemia, which can lead to fetal arrhythmias or death. |
| Fetal Monitoring | Monitor serum potassium, electrolytes, renal function, and ECG periodically. Assess for signs of hyperkalemia (muscle weakness, cardiac arrhythmias). Fetal heart rate monitoring may be indicated if maternal electrolyte disturbances occur. |
| Fertility Effects | No known adverse effects on fertility. Potassium is essential for normal cellular function, and maintaining normokalemia is important for reproductive health. |
■ FDA Black Box Warning
Concentrated potassium chloride solutions (≥ 2 mEq/mL) must be diluted before administration. Rapid infusion or high concentration can cause fatal cardiac arrhythmias due to hyperkalemia.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria, anuria, or azotemiaAdrenal insufficiency (e.g., Addison's disease)Acute dehydrationConcomitant use with potassium-sparing diuretics (e.g., amiloride, spironolactone, triamterene) unless carefully monitoredConditions causing extensive tissue breakdown (e.g., severe burns, crush injury) due to risk of hyperkalemia
| Precautions | Monitor serum potassium levels closely during therapy, Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia, Avoid rapid infusion or high concentrations which can cause cardiac arrest, Do not use in patients with untreated Addison's disease, acute dehydration, heat cramps, or severe renal impairment, Administration may cause local phlebitis and extravasation |
| Food/Dietary | Avoid foods high in potassium: bananas, oranges, potatoes, tomatoes, spinach, avocados, dried fruits, beans, and salt substitutes containing potassium chloride. |
| Clinical Pearls | Administer via central line if concentration > 40 mEq/L to avoid phlebitis. Maximum infusion rate: 10 mEq/hour IV. Monitor ECG for peaked T waves in hyperkalemia. Contraindicated in severe renal impairment or hyperkalemia. Use with caution in patients on ACE inhibitors or potassium-sparing diuretics. |
| Patient Advice | Report symptoms of hyperkalemia: muscle weakness, palpitations, tingling in hands/feet. · Do not take extra potassium supplements or salt substitutes containing potassium. · Advise to follow a low-potassium diet as directed by physician. · Do not stop this medication abruptly without consulting doctor. |
Loading safety data…